Endocyte (ECYT) Inactive 10-K2016 FY Annual report

Filed: 13 Mar 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: AB, abemaciclib, adaptor, Advantagene, aim, alectinib, ALK, anaplastic, Andriole, apalutamide, Arno, Asana, Athenex, ATLAB, Auditor, avelumab, Bavarian, Bayer, Belt, Ben, BioPharma, Black, bolstered, BRAF, breakthrough, bridge, brigatinib, Calithera, CAR, CDK, Ceritinib, Certified, checkpoint, Childhood, chimeric, congressional, crizotinib, crosslinker, crosslinking, CureVac, Custirsen, cytokine, dabrafenib, Dendreon, DexTech, dual, Epidermal, eradication, ESSA, Excellence, expedite, fast, FITC, Fluorescein, gefitinib, Gopichand, GVAX, Hanmi, Helix, Hengrui, hope, hour, inclusion, Innocrin, insight, interaction, intolerant, isothiocyanate, Jensen, Jevtana, Jiangsu, Kadmon, Kelley, kinase, Kite, lymphoma, Lynparza, malignant, Masitinib, mCRPC, MEK, metastatic, modification, Mohamad, mutation, Niraparib, noncash, Nordic, occupancy, olmutinib, Onapristone, OncoGenex, Osteodex, passed, Pharma, PPACA, PR, proPBD, ProstAtak, Prostvac, Provenge, PSA, pyrrolobenzodiazepine, recur, revalued, Rubraca, SAS, Seattle, Seviteronel, Sigma, soft, Sotio, spite, storm, Takeda, Taxotere, Taxpayer, Tecentriq, Tony, Towne, TRACON, trametinib, variability, Victor, Vivian, voluntarily, wake, William, Xavier, Xofigo, Xtandi, Yervoy, Zytiga

Removed: affiliate, Alabama, Assignment, award, began, certification, chose, clarification, compensatory, decreased, discount, distinguish, duly, exhibit, Extensible, fifty, fluctuation, folic, formatted, fulfill, Harper, hedge, Hedging, Indemnification, iv, Language, omitted, Parexel, PhD, physiology, pronouncement, recurrence, redacted, Scot, settle, sought, specialty, Specimen, tarGEtedTreatment, theInternal, thereunder, thereunto, tolerance, undergraduate, undersigned, unrecorded, XBRL, Zeller

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ECYT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 10.20

ENDOCYTE, INC.

SCHEDULE OF TERMS FOR

CHANGE IN CONTROL AND SEVERANCE AGREEMENTS

WITH EXECUTIVE OFFICERS

March 2017


		Termination without Cause or Resignation for Good Reason, prior to a Change in Control or after 12 months following a Change in Control			Termination without Cause or Resignation for Good Reason, within 12 months following a Change in Control
Name of Executive Officer	Date of Agreement	Severance Payment – Percentage of Base Salary	140% COBRA Continuation	Accelerated vesting for equity awards that would have vested over the following	Severance Payment – Percentage of Base Salary	Severance Payment – Percentage of Target Bonus	140% COBRA Continuation	Percentage of unvested equity awards that will immediately vest
Michael A. Sherman	6/17/16	100%	12 months	12 months	200%	200%	24 months	100%
Michael A. Andriole	2/20/17	75%	9 months	9 months	150%	150%	18 months	100%
Alison A. Armour	8/10/15	75%	9 months	9 months	150%	150%	18 months	100%
Beth A. Taylor	5/15/15	75%	9 months	9 months	100%	100%	12 months	100%
Michael A. Brinkley	5/15/15	75%	9 months	9 months	100%	100%	12 months	100%
Christopher P. Leamon	5/15/15	75%	9 months	9 months	150%	150%	18 months	100%
Katherine K. Parker	5/15/15	75%	9 months	9 months	100%	100%	12 months	100%

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.